Improving NASH with a little help from thyromimetics.

Traditionally, non-alcoholic steatohepatitis (NASH) has been associated with insulin resistance-related clinical conditions, such as overweight and type 2 diabetes. They report an early reduction in liver fat content, with a mean difference from baseline over placebo of -22-5% (95% CI -32-9 to -12-2, p<0-0001) at 12 weeks, and a significant improvement in the pro-atherogenic lipid profile of NASH patients treated with resmetirom. Whether resmetirom works better in patients with more pronounced hepatic hypothyroidism is unknown, and most patients in this trial presumably had low rather than high normal baseline thyroid stimulating hormone concentrations. [Extracted from the article]